secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001104659-26-027953
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience raises $120M via PIPE to fund ALTO-207 Phase 3 in TRD
-----------------------------------------------------------------------

- Gross proceeds ~$120M from sale of 2.9M shares at $20.00 and 3.1M pre-funded warrants at $19.9999.
- Financing led by Commodore Capital with participation from new and existing biotech investors.
- Proceeds to fund ALTO-207 (pramipexole/ondansetron combo) through planned Phase 3 TRD study and potential NDA.
- Plan to initiate ALTO-207 Phase 2b in H1 2026 and Phase 3 in early 2027; pro forma cash ~$275M as of Feb 28, 2026.
- Closing expected March 17, 2026; Jefferies, BofA, TD Cowen, Stifel, William Blair, Baird as placement agents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000110465926027953/0001104659-26-027953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000110465926027953/tm268876d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-027953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer